Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00104065 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant
A Phase 2 study, sponsored by CuraGen Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00104065: Completed Phase 2 study, sponsored by CuraGen Corporation.
NCT00104065 is a Phase 2 study that has completed, run by CuraGen Corporation. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00104065, a Phase 2 study, has completed, sponsored by CuraGen Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
CG53135-05, a recombinant human fibroblast growth factor-20 (rhFGF-20) protein, is under investigation for the prevention of oral mucositis. Oral mucositis is a commonly occurring side effect of high-dose chemotherapy in patients undergoing autologous hematopoietic stem cell transplant. The objective of this Phase II trial is to evaluate the safety and efficacy of CG53135-05 when administered as a single dose to patients at risk for developing oral mucositis.
Interventions
- DRUG CG53135-05, velafermin
Trial Details
| Field | Value |
|---|---|
| Start Date | 2005-01 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
What the finished NCT00104065 record still lists
NCT00104065 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which CG53135-05, velafermin is the first listed.
NCT00104065 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00104065 about?
NCT00104065 is a clinical study titled "Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant". CG53135-05, a recombinant human fibroblast growth factor-20 (rhFGF-20) protein, is under investigation for the prevention of oral mucositis. Oral mucositis is a commonly occurring side effect of high-dose chemotherapy in patients undergoing autologous hematopoietic stem cell transplant. The objectiv...
What is the current status of trial NCT00104065?
This trial is currently completed. It is a Phase 2 study. The study started on 2005-01. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00104065?
The interventions under investigation include: CG53135-05, velafermin (DRUG).
Who is sponsoring clinical trial NCT00104065?
This trial is sponsored by CuraGen Corporation, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia